You are here: Industry Insights > Motixafortide

News List

BioLineRx Initiates ARDS Trial americanpharmaceuticalreview
December 03, 2020
BioLineRx announced the Company's lead drug candidate, the CXCR4-inhibitor Motixafortide, will be evaluated in an investigator-initiated clinical trial in patients suffering from acute respiratory distress syndrome (ARDS) secondary to COVID-19 and ...
BioLineRx Announces Initiation of Phase 1b Clinical Trial in Patients with Acute Respiratory Distress Syndrome (ARDS) Secondary to COVID-19 and Other Respiratory Viral Infections prnewswire
November 19, 2020
BioLineRx Ltd., a clinical-stage biopharmaceutical Company focused on oncology, announced that the Company's lead drug candidate, the CXCR4-inhibitor Motixafortide, will be evaluated in an investigator-initiated clinical trial in patients suffering ...
BioLineRx Announces Positive Results from Trial of Motixafortide in Stem Cell Mobilization americanpharmaceuticalreview
November 11, 2020
BioLineRx announced positive results from a planned interim analysis of the ongoing GENESIS Phase 3 trial of motixafortide for stem cell mobilization (SCM) in multiple myeloma patients.
BioLineRx achieves enrolment target in phase 3 GENESIS Trial for planned interim analysis pharmaceutical-business-review
August 25, 2020
BioLineRx announced that a sufficient number of patients (~65% of the original planned sample size) have been enrolled in the ongoing GENESIS Phase 3 trial to allow for an interim efficacy analysis to take place in the second half of 2020.
BioLineRx Announces Notice of Allowance from USPTO for Motixafortide, Anti-PD-1 Combination americanpharmaceuticalreview
March 05, 2020
BioLineRx announced a Notice of Allowance has been issued by the United States Patent and Trademark Office (USPTO) for a patent application claiming the use of motixafortide (BL-8040).
BioLineRx Receives Orphan Drug Designation for Motixafortide for Pancreatic Cancer in Europe americanpharmaceuticalreview
January 19, 2020
BioLineRx announced the European Commission (EC) has granted Orphan Drug Designation to its lead oncology candidate, Motixafortide (BL-8040), for the treatment of pancreatic cancer, based on a positive opinion from the Committee for ...